NCT00993512 - Safety Study of Amphinex Based Photochemical Internalisation (PCI) of Bleomycin in Patients With Cutaneous Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions

Head and Neck NeoplasmsSkin Neoplasms

Interventions

DRUG

Amphinex (TPCS2a)

intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.

DRUG

Bleomycin

intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.

OTHER

Illumination with CeramOptec laser

intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.

Trial Locations (1)

University College London Hospital, London